Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News

News :
Latest NewsCompaniesMarketsForexCryptocurrenciesCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

H Lundbeck A/S : Lundbeck increases its share capital by 11,497 shares (0.0058 % of outstanding shares) as a result of exercise of employee warrants

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2020 | 05:17am EST

Valby, Denmark, 19 February 2020 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 57,485 as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 11,497 shares at DKK 113. Proceeds to the company are DKK 1,299,161 (approximately USD 0.192 million). The increase corresponds to approximately 0.0058 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.

Lundbeck's current share capital amounts to DKK 995,683,625. The capital increase is expected to be finalized shortly, and the total number of voting rights and the total share capital will after this capital increase be:


Number of shares Nominal value            Number of votes               
(nominal value DKK of shares
5) (DKK)
199,148,222 995,741,110 199,148,222


Lundbeck contacts


Palle Holm Olesen

Vice President, Investor Relations


+45 30 83 24 26



Mads Kronborg

Senior Director, Corporate Communication


+45 36 43 40 00



About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind (https://webmaster.lundbeck.com/N2/Content/wwww.lundbeck.com/global/about-us/progress-in-mind). 

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.




H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311




(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news
05:17aH LUNDBECK A/S : Lundbeck increases its share capital by 11,497 shares (0.0058 % of outstanding shares) as a result of exercise of employee warrants
05:16aNEWS HIGHLIGHTS : Top Company News of the Day
05:16aNEWS HIGHLIGHTS : Top Global Markets News of the Day
05:16aNAVIGANT RESEARCH : Report Shows Global Market for Modular Microgrids Is Expected to Experience 28% Compound Annual Growth Rate from 2020-2029
05:15aOil up on slowing pace of coronavirus, Venezuela sanctions
05:15aKSB SE & CO. KGAA : Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
05:15aMETAFINA GMBH : Successful start to the new year
05:14aP I A C A : Hero of PIA Air Marshal Arshad Malik will be never zero
05:13aPRECISION TSUGAMI CHINA : Continuing connected transactions renewal of the technology license agreement, the master sales agreement, the master purchase agreement and the proposed annual caps
05:13aNigeria to kick off gas flare commercialisation from 45 sites
Latest news